Desensitization with daratumumab in a pediatric patient with thalassemia major and high donor‐specific antibody prior to haploidentical transplantation-Reference-Cited by-同舟云学术

Desensitization with daratumumab in a pediatric patient with thalassemia major and high donor‐specific antibody prior to haploidentical transplantation

Published:2024-09-03 Issue: Volume: Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Suwantarat Nuttra¹,Iamsirirak Pornchanok¹,Chanapai Jiraporn¹,Pakakasama Samart²,Andersson Borje S³,Boelens Jaap Jan⁴⁵,Anurathapan Usanarat²^ORCID,Hongeng Suradej²^ORCID

Affiliation:

1. Department of Pediatrics Samitivej Children's Hospital Bangkok Thailand

2. Department of Pediatrics Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand

3. Department of Stem Cell Transplantation and Cellular Therapy University of Texas MD Anderson Cancer Center Houston Texas USA

4. Department of Pediatrics Stem Cell Transplantation and Cellular Therapies Service MSK Kids Memorial Sloan Kettering Cancer Service New York New York USA

5. Department of Pediatrics Weill Cornell Medicine New York New York USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.31311

Reference12 articles.

1. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen;Anurathapan U;Biol Blood Marrow Transplant,2020

2. Complement‐binding donor‐specific anti‐HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation;Ciurea SO;Biol Blood Marrow Transplant,2015

3. Risk and prevention of graft failure in patients with preexisting donor‐specific HLA antibodies undergoing unmanipulated haploidentical SCT;Yochihara S;Bone Marrow Transplant,2012

4. Outcomes of patients who underwent treatment for anti‐HLA donor‐specific antibodies before receiving a haploidentical hematopoietic stem cell transplant;Lipsitt A;Pediatr Blood Cancer,2022

5. Treatment of allosensitized patients receiving allogeneic transplantation;Ciurea SO;Blood Adv,2021